<?xml version="1.0" encoding="UTF-8"?>
<p>Another meta-analysis including 3,117 patients of 38 RCTs in China showed an overall response rate in treating lung cancer treated with lentinanIV (1–1.5 mg/d, 2–8 weeks, depending on the study), a main ingredient of 
 <italic>Lentinula edodes</italic>, was increased from 43.3% of chemotherapy alone to 56.9% of lentinan plus chemotherapy. Compared with chemotherapy alone, lentinan plus chemotherapy showed more efficacy in treating lung cancer (pooled RR 0.79, 95% CI: 0.74–0.85) (
 <xref rid="B66" ref-type="bibr">Zhang et al., 2018</xref>).
</p>
